Free Newsletter
SPOTLIGHT: Biovail and its execs charged with fraud
Free newsletter via e-mail
Tools
The Securities and Exchange Commission charged Biovail, its founder Eugene Melnyk (photo), and three other current and former executives with fraud, alleging that they repeatedly overstated earnings and hid losses. The company will pay a $10 million fine to settle its case, but charges against Melnyk, former CFO Brian Crombie, current controller John Miszuk, and current CFO Kenneth Howling remain outstanding. The two current executives have been reassigned to non-officer roles within the company. Release | Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
